-
Clinical, Cosmetic and Investigational Dermatology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Fixed drug eruption induced by atenolol
Rapid Communication
(3341) Views (704) Full article downloads
Authors: H Belhadjali, O Trimech, M Youssef, I Elhani, J Zili
Published Date April 2009
Volume 2008:1 Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CCID.S4057
H Belhadjali, O Trimech, M Youssef, I Elhani, J Zili
Department of Dermatology, Fattouma Bourguiba Hospital, Monastir, Tunisia
Abstract: Fixed drug eruption (FDE) is characterized by recurrent well-defined lesions in the same location each time the responsible drug is taken. We report here a case of multiple FDE induced by atenolol in a 48-year-old woman confirmed by positive patch test in previously affected sites. Beta-blockers-induced FDE are very rare. Only two cases had been reported in the literature. To the best of our knowledge, this is the first case reported of atenolol-induced FDE confirmed by a positive patch test.
Keywords: fixed drug eruption, patch test, atenolol, beta-blockers
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Morgellons disease: Analysis of a population with clinically confirmed microscopic subcutaneous fibers of unknown etiology
- Update on the management of chronic eczema: new approaches and emerging treatment options
- Management of superficial basal cell carcinoma: focus on imiquimod
- An update on the management of acne vulgaris




